Pharmaceuticals

A notable trend in the Next Generation Complement Therapeutics Market is the development of targeted, long-acting therapies for complement-mediated conditions

March 23, 2026March 24, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Next Generation Complement Therapeutics Market By The End Of 2030?

The next generation complement therapeutics market has experienced rapid growth in recent years. It is anticipated to expand from $7.38 billion in 2025 to $8.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 16.0%. The growth observed in the past can be linked to the restricted availability of complement-targeting therapeutics, a reliance on conventional immunosuppressive therapies, the increasing prevalence of rare hematologic and autoimmune disorders, the regulatory approvals secured for first-generation complement inhibitors, and an escalation in clinical trials conducted in hematology and ophthalmology.

The next generation complement therapeutics market size is anticipated to experience significant expansion in the coming years. This sector is projected to reach $15.29 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.6%. This expected growth during the forecast period can be attributed to various factors, such as the creation of novel c3, c5, factor b, and factor d inhibitors, the increased utilization of combination therapy approaches, the growing acceptance of gene and RNA-based medicines, rising investment in rare disease research, and an increase in healthcare spending on advanced immune therapies. Prominent trends expected in this forecast period include the increasing adoption of targeted complement therapies for rare diseases, an expansion in both monotherapy and adjunctive therapy strategies, a rise in the application of biologics and small molecule complement inhibitors, the broadening of applications across ophthalmology, hematology, and immunology, and the integration of personalized medicine and gene-based therapeutics.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27360&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Next Generation Complement Therapeutics Market?

The increasing occurrence of chronic diseases is projected to fuel the expansion of the next-generation complement therapeutics market in the coming years. These conditions are enduring health issues demanding continuous care to manage symptoms and enhance quality of life. Sedentary lifestyles, which restrict physical activity, disrupt metabolism, and increase long-term health dangers, contribute to the escalating number of chronic diseases. Next-generation complement therapeutics address chronic illnesses by precisely targeting and regulating the hyperactive complement system to diminish inflammation and avert tissue damage. An example illustrating this trend is seen in June 2024, when the National Health Service, a UK-based government department, reported that 3,615,330 individuals registered with a general practitioner (GP) had received a diagnosis of non-diabetic hyperglycemia or pre-diabetes (a state characterized by elevated blood sugar levels, insufficient for a diabetes classification) in 2023. This represented an 18% surge from the 3,065,825 cases recorded in 2022. Consequently, the increasing incidence of chronic diseases is stimulating the expansion of the next-generation complement therapeutics market.

Which Segment Classifications Shape The Next Generation Complement Therapeutics Market?

The next generation complement therapeutics market covered in this report is segmented –

1) By Type Of Therapy: Monotherapy, Adjunctive Therapy

2) By Molecule Type: Biologic, Small Molecule

3) By Route Of Administration: Intravenous, Oral, Intravitreal, Subcutaneous

4) By Indication: Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) Secondary To Age-Related Macular Degeneration, Generalized Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome, Other Indications

5) By Therapeutic Area: Hematology, Ophthalmology, Neurology, Immunology Or Rheumatology, Other Therapeutic Areas

Subsegments:

1) By Monotherapy: C3 Inhibitors, C5 Inhibitors, Factor D Inhibitors, Factor B Inhibitors, C1 Inhibitors, MASP-2 Inhibitors

2) By Adjunctive Therapy: Combination With Immunosuppressants, Combination With Steroids, Combination With Plasma Exchange, Combination With Biologics, Combination With Chemotherapeutics, Combination With Anticoagulants

How Are Trends Impacting The Next Generation Complement Therapeutics Market?

Companies operating within the Next Generation Complement Therapeutics market are focusing on developing innovative solutions, such as targeted C5 complement inhibitors, to meet the rising demand for effective treatments for rare and severe complement-mediated diseases. Targeted C5 complement inhibitors are designed to selectively block the C5 protein in the complement cascade, preventing the formation of the membrane attack complex, which is a critical step in immune-mediated tissue damage. For instance, in February 2024, Chugai Pharmaceutical Co., Ltd., a Japan-based biopharmaceutical company, launched PEGPH20 (Pegcetacoplan), an innovative C5-targeted complement inhibitor. PEGPH20 is a synthetic peptide conjugate designed to selectively inhibit complement C5 activation, thereby preventing hemolysis and inflammation associated with conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and other complement-driven disorders. The therapy provides benefits such as subcutaneous administration, improved patient compliance, and a favorable safety profile compared to traditional systemic complement inhibitors.

Which Companies Are Expanding Their Footprint In The Next Generation Complement Therapeutics Market?

Major companies operating in the next generation complement therapeutics market are AstraZeneca PLC, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Genmab A/S, Mallinckrodt Pharmaceuticals Ltd., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Omeros Corporation, CANbridge Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Molecular Partners AG, NovelMed Therapeutics Inc., InflaRx GmbH, Amyndas Pharmaceuticals S.A., Kira Pharmaceuticals Inc., ReAlta Life Sciences Inc.

Read the full next generation complement therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-complement-therapeutics-global-market-report

Which Regions Are Projected To Dominate The Next Generation Complement Therapeutics Market In The Coming Years?

North America was the largest region in the next generation complement therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation complement therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next Generation Complement Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27360&type=smp

Browse Through More Reports Similar to the Global Next Generation Complement Therapeutics Market 2026, By The Business Research Company

Payment Gateway Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-gateway-global-market-report

Payment Processor Market Report 2026

https://www.thebusinessresearchcompany.com/report/payment-processor-global-market-report

Quantum Technology Market Report 2026

https://www.thebusinessresearchcompany.com/report/quantum-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795